PCVX at a glance
Vaxcyte, Inc. (PCVX, SEC CIK 1649094) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Vaxcyte, Inc. (PCVX) shares worth $2.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Dhaliwal Harpreet S. on November 11, 2026 of 9,345 shares at $68.16 per share.
- In the last 90 days, PCVX insiders reported 0 open-market purchases ($0) and 17 open-market sales ($5.2M) on Form 4, a net sale of $5.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 17 sells
- Net −$5.2M
- 13F holders
- 33 funds
- $2.7B · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of proprietary pneumococcal conjugate vaccines
- New manufacturing agreement with Lonza Ltd effective January 2026 for development and commercial supply of vaccine components
- Strategic move to secure long-term manufacturing capacity with fees in mid- to high-eight-figures Swiss Francs annually through 2038 plus renewals
- License received from Lonza: perpetual, irrevocable, royalty-free rights to use Lonza’s intellectual property related to product and manufacturing process
- Contract includes termination rights with termination fees in low-eight-figures Swiss Francs, ensuring operational flexibility and risk mitigation
Risk Factors
- Cybersecurity breach risk with potential regulatory fines, investigations, operational disruptions, and reputational harm
- SVP IT with 30+ years experience leads cybersecurity risk management and incident response
- Cybersecurity incident escalation to President and CFO, with audit committee oversight and quarterly reporting
Management Discussion & Analysis
- No revenue generated in FY 2026 as Vaxcyte is clinical-stage; net losses $766.6M in 2025 vs $463.9M in 2024 vs $402.3M in 2023
- Operating losses increased due to advancing clinical trials and manufacturing scale-up; cash, equivalents, investments $2.44B as of Dec 31, 2025
- Best performing pipeline: VAX-31 Phase 3 adult PCV program initiated with ~3,560 adults dosed; FDA breakthrough therapy designation expanded to pneumonia prevention
- Capital raise: February 2026 public offering gross proceeds $632.5M from 12.65M shares at $50 each
- Forward outlook: Phase 3 data awaited late 2026 (adult) and first half 2027 (infant); planning BLA submission post Phase 3; risks include development timelines and regulatory approvals
AI summary of the PCVX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added AI risk: expanded operational use of AI could trigger privacy-law violations, regulatory scrutiny, or reputational harm
- Most materially updated regulatory risk: FDA may require expanded trials, additional safety data, or post-marketing surveillance for vaccine approvals
- Regulatory compliance risk: federal vaccine-policy changes could alter ACIP-linked coverage, reimbursement, liability protections, and state mandates
- Competitive risk: Pfizer plans PCV25 pediatric Phase 3 completion in Q2 2029, with regulatory submission planned in 2029
- Liquidity risk: $2.3 billion cash, cash equivalents, and investments expected to fund operations for at least 12 months
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved products or commercial sales
- Net loss $297.1M vs $212.8M YoY, operating loss $308.3M vs $242.4M
- R&D expense $270.3M, up 28.8% YoY, driven by PCV manufacturing and OPUS trials
- Cash, equivalents and investments $2.3B, including $0.1B cash and $2.1B investments
- Operating cash outflow $737.2M; October offerings generated approximately $1.15B gross proceeds, outlook funding through at least 12 months
AI summary of the PCVX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Vaxcyte reported financial results for the quarter ended September 30, 2026
- Full quarterly results and management commentary are in Exhibit 99.1 accompanying the 8-K
Item EX-99.1: Item EX-99.1
- OPUS-1 Phase 3 met all primary endpoints across VAX-31’s 31-valent adult program, materially advancing the planned BLA
- VAX-31 showed safety comparable to PCV20 and PCV21, though serotypes 3 and 12F missed the stricter PCV21 noninferiority threshold
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 points investors to Item 1.01 for details of any direct financial obligation
- Financial impact depends on the referenced agreement’s payment terms, commitments and timing
Item 8.01: Other Events
- Concurrent offerings closed October 9, 2026, raising approximately $1.103 billion net for Vaxcyte
- Equity financing included 8,584,375 shares after full option exercise, creating substantial shareholder dilution
Item 1.01: Entry into a Material Definitive Agreement
- $575M raised through 1.50% convertible senior notes due October 2032, strengthening funding capacity at low cash interest cost
- Semiannual interest payments begin April 15, 2027, creating a long-dated fixed financing obligation
Item 7.01: Regulation FD Disclosure
- Positive topline OPUS-1 Phase 3 data for VAX-31, a 31-valent pneumococcal conjugate vaccine candidate
- Adult trial assessed safety, tolerability and immunogenicity, supporting potential advancement toward regulatory submission
Item 8.01: Other Events
- Vaxcyte made an investor slide presentation available on October 5, 2026
- Exhibit 99.2 contains the substantive disclosure and may provide updates on pipeline programs, clinical data, or corporate strategy
Item EX-99.1: Item EX-99.1
- OPUS-1 Phase 3 success: VAX-31 met all primary endpoints across studied age groups, materially de-risking its adult regulatory path
- Broader coverage with preserved immunity: 28 shared serotypes met noninferiority, while three unique serotypes and 20B achieved superiority
Item EX-99.2: Item EX-99.2
- OPUS-1 Phase 3 success: all 32 immunogenicity comparisons met noninferiority, supporting VAX-31’s planned BLA submission
- Broad coverage advantage: designed for 95% of adult IPD and 88% of pneumococcal pneumonia, 13-36% and 19-31% above standard vaccines
AI summaries of PCVX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PCVX
Don't miss the next PCVX filing
- Alerts as it files. A push when PCVX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PCVX, by share count.
- Ask anything. An AI agent that reads every PCVX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Dhaliwal Harpreet S. | Sell | Nov 11, 2026 | 9,345 | $68.16 |
| Dhaliwal Harpreet S. | Sell | Nov 11, 2026 | 7,135 | $67.33 |
| Dhaliwal Harpreet S. | Sell | Nov 11, 2026 | 520 | $68.82 |
| Dhaliwal Harpreet S. | M | Nov 11, 2026 | 17,000 | - |
| Dhaliwal Harpreet S. | M | Nov 11, 2026 | 17,000 | $24.79 |
| Wassil Jim | M | Nov 2, 2026 | 2,250 | - |
| Cowan Elvia | Sell | Nov 2, 2026 | 586 | $61.55 |
| Wassil Jim | M | Nov 2, 2026 | 2,250 | $5.35 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$468.0M | -$569.5M | -$923.7M |
| Net Income | -$402.3M | -$463.9M | -$766.6M |
| Balance Sheet | |||
| Total Assets | - | $3.5B | $3.0B |
| Equity | $1.2B | $3.3B | $2.7B |
| ROE | -32.4% | -14.0% | -28.5% |
| Per Share | |||
| EPS | $-4.14 | $-3.80 | $-5.63 |
| Cash Flow | |||
| Operating CF | -$296.8M | -$452.6M | -$655.6M |
| CapEx | $16.1M | $22.4M | $13.7M |
Source: XBRL data in Vaxcyte, Inc. (PCVX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PCVX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 33 | $2.69B |
| Q2 2026 | 33 | $3.83B |
| Q1 2026 | 35 | $3.32B |
| Q4 2025 | 27 | $2.47B |
| Q3 2025 | 28 | $2.00B |
| Q2 2025 | 28 | $1.85B |
| Q1 2025 | 26 | $1.63B |
| Q4 2024 | 23 | $3.14B |
- Goldman Sachs Group+982.2K (+73%)
- T. Rowe Price Group+542.0K (+18%)
- Principal Financial Group+322.3K (+4179%)
- Ameriprise Financial+280.0K (+64%)
- Morgan Stanley+265.6K (+33%)
- D.E. Shaw & Co−470.5K (-25%)
- Two Sigma Investments−174.7K (-64%)
- JPMorgan Chase & Co−122.4K (-10%)
- State Street Corp−119.6K (-2%)
- Citigroup−91.1K (-45%)
- Citadel Advisors LLC+154.2K
- Blackstone Group+4.3K
- FMR LLC (Fidelity)−20.85M
- Renaissance Technologies LLC−19.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 233 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PCVX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Oct 9, 2026 | - | Analysis | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 8-K | Oct 5, 2026 | - | Analysis | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
PCVX SEC filings: frequently asked questions
Are PCVX insiders buying or selling?
In the last 90 days, Vaxcyte, Inc. (PCVX) officers, directors and 10% owners reported no open-market purchases and 17 open-market sales worth $5.2 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PCVX stock?
As of September 30, 2026, the largest Vaxcyte, Inc. (PCVX) holders among the 13F filers tracked by SignalX were BlackRock ($693.0 million), Vanguard Capital Management LLC ($373.9 million), Vanguard Portfolio Management LLC ($373.8 million), State Street Corp ($297.7 million), T. Rowe Price Group ($200.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in PCVX's latest 10-K?
In the 10-K filed February 24, 2026, Vaxcyte, Inc. (PCVX) flagged: Cybersecurity breach risk with potential regulatory fines, investigations, operational disruptions, and reputational harm. SVP IT with 30+ years experience leads cybersecurity risk management and incident response. (AI summary of the Risk Factors section.)
What did PCVX report in its latest 8-K?
Vaxcyte, Inc. (PCVX) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Vaxcyte reported financial results for the quarter ended September 30, 2026.
What are the latest PCVX SEC filings?
Vaxcyte, Inc. (PCVX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 13, 2026.
What is PCVX's SEC CIK number?
Vaxcyte, Inc. (PCVX)'s SEC Central Index Key (CIK) is 1649094. EDGAR lists every PCVX filing under that number.
Ask anything about PCVX
The research agent reads PCVX's filings, financials, insider trades and 13F holders, then answers with sources.